Clinical Trial Update: Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of GS-5806 (presatovir) in healthy volunteers infected with respiratory syncytial virus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• GS-5806 (presatovir)

Snippet

Sponsor: Gilead Sciences | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED